Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
25 studies found for:    Duke Psychiatry | Open Studies | United States, North Carolina
Show Display Options
Rank Status Study
1 Recruiting Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD
Condition: Attention-Deficit/Hyperactivity Disorder
Intervention: Drug: Methylphenidate HCl ER Capsules
2 Recruiting Pain Management Using Mobile Technology in Veterans With PTSD and TBI
Conditions: Chronic Pain;   Posttraumatic Stress Disorders;   Traumatic Brain Injury
Intervention: Device: NeuroSky MindWave Mobile
3 Recruiting Sleep Dysfunction and Neurocognitive Outcomes in Adolescent ADHD
Condition: Attention Deficit Hyperactivity Disorder
Intervention:
4 Recruiting Carolina Alcohol and Drug Resources
Condition: HIV
Intervention: Behavioral: Comprehensive substance abuse services
5 Recruiting Hepatitis C Alcohol Reduction Treatment
Condition: Hepatitis C, Chronic; AUD
Interventions: Behavioral: Brief alcohol counseling;   Behavioral: Group and Individual Therapy Sessions
6 Recruiting Mobile Health Application for Family and Behavioral Health Provider Communication
Conditions: Posttraumatic Stress Disorder;   Anger
Intervention: Behavioral: Connectd mobile application
7 Recruiting Feeling and Body Investigators
Condition: Functional Abdominal Pain
Interventions: Behavioral: Feeling and Body Investigators with Functional Abdominal Pain;   Behavioral: Treatment Strategies
8 Not yet recruiting A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
Condition: Attention Deficit Disorder With Hyperactivity
Intervention: Drug: Aptensio XR
9 Not yet recruiting A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD
Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: Aptensio XR;   Drug: Placebo
10 Recruiting Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a
Condition: ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)
Interventions: Drug: CERC-501;   Drug: placebo
11 Recruiting Post Admission Cognitive Therapy (PACT) for the Inpatient Treatment of Military Personnel With Suicidal Behaviors
Conditions: Suicide, Attempted;   Suicidal Ideation Active
Intervention: Behavioral: Post Admission Cognitive Therapy (PACT)
12 Recruiting Software Treatment for Actively Reducing Severity of ADHD - Follow Up
Condition: Attention Deficit Disorder With Hyperactivity
Intervention: Device: EVO
13 Recruiting Software Treatment for Actively Reducing Severity of ADHD
Condition: Attention Deficit Disorder With Hyperactivity
Intervention: Device: EVO
14 Recruiting A Long-term Safety Study of Intranasal Esketamine in Treatment-resistant Depression
Condition: Depressive Disorder, Treatment-Resistant
Intervention: Drug: Intranasal Esketamine
15 Recruiting Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)
Condition: Obsessive Compulsive Disorder
Interventions: Drug: sertraline;   Behavioral: psychotherapy
16 Recruiting A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Condition: Treatment-resistant Depression
Interventions: Drug: Esketamine;   Drug: Placebo;   Drug: Duloxetine (Oral Antidepressant);   Drug: Escitalopram (Oral antidepressant);   Drug: Sertraline (Oral Antidepressant);   Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)
17 Recruiting MOMENTUM 3 Continued Access Protocol
Condition: Advanced Refractory Left Ventricular Heart Failure
Intervention: Device: HeartMate 3 LVAS
18 Recruiting An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
Condition: Asymptomatic Amyloid-positive
Interventions: Drug: JNJ-54861911, 5 mg;   Drug: JNJ-54861911, 25 mg;   Drug: Placebo
19 Recruiting Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Condition: Huntington's Disease
Intervention:
20 Recruiting A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Biological: PF-06252616;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.